Shares of Celldex Therapeutics (CLDX) have gained 1.7% over the past four weeks to close the last trading session at $36.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $69.14 indicates a potential upside of 87.3%.The mean estimate comprises seven short-term price targets with a standard deviation of $20.15. While the lowest estimate of $27 indicates a 26.9% decline from the ...